Business · 23/10/20261 min read
ImmVira presents clinical data from three bladder cancer studies at ESMO 2026
Summary
SUZHOU, China, Oct. 22, 2026 — ImmVira Group ("ImmVira") today announced that updated clinical data from three bladder cancer studies of its leading oncolytic immunotherapy candidate, MVR-T3011, will be pre...